Figures computed from official regulatory filings — .
Analysttarget 7 USD (+653%)
Ownershipinsiders 6.62% · institutions 39.11% · short 4.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Werewolf Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
19 buys168 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| EVNIN LUKEtrack record | Sell | $33.3K | SEC |
| EVNIN LUKEtrack record | Sell | $11.4K | SEC |
| EVNIN LUKEtrack record | Sell | $47.1K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $9.7K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $136.2K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $51.7K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $3.7K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $46.9K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $3.3K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $63.6K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $4.5K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $9.1K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $127.7K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $1.1K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $93.1K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $6.6K | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Sell | $15.9K | SEC |
| EVNIN LUKEtrack record | Sell | $28.5K | SEC |
| EVNIN LUKEtrack record | Sell | $8.8K | SEC |
| EVNIN LUKEtrack record | Sell | $24.2K | SEC |
| EVNIN LUKEtrack record | Sell | $10K | SEC |
| EVNIN LUKEtrack record | Sell | $13.3K | SEC |
| EVNIN LUKEtrack record | Sell | $12.5K | SEC |
| EVNIN LUKEtrack record | Sell | $37.8K | SEC |
| EVNIN LUKEtrack record | Sell | $38.8K | SEC |